Calidi Biotherapeutics Stock Performance
| CLDI Stock | 0.82 0.06 7.89% |
The firm shows a Beta (market volatility) of 1.72, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Calidi Biotherapeutics will likely underperform. At this point, Calidi Biotherapeutics has a negative expected return of -0.99%. Please make sure to confirm Calidi Biotherapeutics' treynor ratio, accumulation distribution, period momentum indicator, as well as the relationship between the potential upside and day median price , to decide if Calidi Biotherapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Calidi Biotherapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's fundamental indicators remain fairly strong which may send shares a bit higher in March 2026. The recent confusion may also be a sign of long-lasting up-swing for the firm traders. ...more
| Begin Period Cash Flow | 2.2 M | |
| Total Cashflows From Investing Activities | -16 K |
Calidi Biotherapeutics Relative Risk vs. Return Landscape
If you would invest 151.00 in Calidi Biotherapeutics on November 27, 2025 and sell it today you would lose (71.18) from holding Calidi Biotherapeutics or give up 47.14% of portfolio value over 90 days. Calidi Biotherapeutics is currently does not generate positive expected returns and assumes 3.6236% risk (volatility on return distribution) over the 90 days horizon. In different words, 32% of stocks are less volatile than Calidi, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Calidi Biotherapeutics Target Price Odds to finish over Current Price
The tendency of Calidi Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 0.82 | 90 days | 0.82 | about 88.49 |
Based on a normal probability distribution, the odds of Calidi Biotherapeutics to move above the current price in 90 days from now is about 88.49 (This Calidi Biotherapeutics probability density function shows the probability of Calidi Stock to fall within a particular range of prices over 90 days) .
Calidi Biotherapeutics Price Density |
| Price |
Predictive Modules for Calidi Biotherapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Calidi Biotherapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Calidi Biotherapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Calidi Biotherapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Calidi Biotherapeutics is not an exception. The market had few large corrections towards the Calidi Biotherapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Calidi Biotherapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Calidi Biotherapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -1.17 | |
β | Beta against Dow Jones | 1.72 | |
σ | Overall volatility | 0.25 | |
Ir | Information ratio | -0.3 |
Calidi Biotherapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Calidi Biotherapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Calidi Biotherapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Calidi Biotherapeutics generated a negative expected return over the last 90 days | |
| Calidi Biotherapeutics has some characteristics of a very speculative penny stock | |
| Calidi Biotherapeutics has high historical volatility and very poor performance | |
| Calidi Biotherapeutics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (22.21 M) with profit before overhead, payroll, taxes, and interest of 31 K. | |
| Calidi Biotherapeutics generates negative cash flow from operations | |
| Calidi Biotherapeutics has a poor financial position based on the latest SEC disclosures | |
| About 13.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: Analysts Offer Insights on Healthcare Companies Soligenix and Boston Scientific - The Globe and Mail |
Calidi Biotherapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Calidi Stock often depends not only on the future outlook of the current and potential Calidi Biotherapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Calidi Biotherapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 664.4 K | |
| Cash And Short Term Investments | 9.6 M |
Calidi Biotherapeutics Fundamentals Growth
Calidi Stock prices reflect investors' perceptions of the future prospects and financial health of Calidi Biotherapeutics, and Calidi Biotherapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Calidi Stock performance.
| Return On Asset | -1.2 | ||||
| Current Valuation | (1.65 M) | ||||
| Shares Outstanding | 7.17 M | ||||
| Price To Book | 0.78 X | ||||
| Price To Sales | 50.83 X | ||||
| EBITDA | (19.73 M) | ||||
| Total Debt | 7.04 M | ||||
| Book Value Per Share | 0.98 X | ||||
| Cash Flow From Operations | (19.69 M) | ||||
| Earnings Per Share | 0.36 X | ||||
| Total Asset | 14.18 M | ||||
| Retained Earnings | (121.72 M) | ||||
About Calidi Biotherapeutics Performance
By evaluating Calidi Biotherapeutics' fundamental ratios, stakeholders can gain valuable insights into Calidi Biotherapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Calidi Biotherapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Calidi Biotherapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Things to note about Calidi Biotherapeutics performance evaluation
Checking the ongoing alerts about Calidi Biotherapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Calidi Biotherapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Calidi Biotherapeutics generated a negative expected return over the last 90 days | |
| Calidi Biotherapeutics has some characteristics of a very speculative penny stock | |
| Calidi Biotherapeutics has high historical volatility and very poor performance | |
| Calidi Biotherapeutics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (22.21 M) with profit before overhead, payroll, taxes, and interest of 31 K. | |
| Calidi Biotherapeutics generates negative cash flow from operations | |
| Calidi Biotherapeutics has a poor financial position based on the latest SEC disclosures | |
| About 13.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: Analysts Offer Insights on Healthcare Companies Soligenix and Boston Scientific - The Globe and Mail |
- Analyzing Calidi Biotherapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Calidi Biotherapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Calidi Biotherapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Calidi Biotherapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Calidi Biotherapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Calidi Biotherapeutics' stock. These opinions can provide insight into Calidi Biotherapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Calidi Stock analysis
When running Calidi Biotherapeutics' price analysis, check to measure Calidi Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Calidi Biotherapeutics is operating at the current time. Most of Calidi Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Calidi Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Calidi Biotherapeutics' price. Additionally, you may evaluate how the addition of Calidi Biotherapeutics to your portfolios can decrease your overall portfolio volatility.
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios |